Current Headlines

  1. Numerate And Lundbeck Partner To Apply AI Drug Discovery To Unlock Challenges Of Neuroscience Research
    1/7/2019

    Numerate, Inc., a data-driven drug design company applying artificial intelligence (AI) to transform drug discovery, announced a multi-target research collaboration with Lundbeck Pharmaceutical to identify clinical candidates for the treatment of disorders in the central nervous system, including depression, psychosis, seizure and neurodegenerative disorders

  2. CytoReason Signs Collaboration Agreement With Pfizer Inc. To Utilize CytoReason’s Machine Learning Model Of The Immune System For Drug Discovery
    1/7/2019

    CytoReason, a leader in machine learning for drug discovery and development, announced recently that it has entered into a collaboration agreement with Pfizer Inc. (NYSE:PFE) that will leverage CytoReason’s cell-centered models of the immune system

  3. Cellectar Provides Update On Phase 1 Trial Of CLR 131 In Relapsed/Refractory Multiple Myeloma
    1/7/2019

    Cellectar Biosciences (Nasdaq: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced median overall survival (mOS) in Cohorts 1-4 of the company’s ongoing Phase 1 clinical trial evaluating CLR 131 for the treatment of relapsed/refractory (R/R) multiple myeloma (MM)

  4. Exscientia Initiates Sixth AI Drug Discovery Partnership
    1/7/2019

    Exscientia to receive up to CHF 67 million in upfront payments, research support, and milestone payments in discovery collaboration with Roche

  5. Biohaven Announces Acceptance Of Investigational New Drug (IND) Filing For Rimegepant In China
    1/7/2019

    iohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) ("Biohaven") and its wholly-owned Asia-Pacific subsidiary company, BioShin, announced today the National Medical Products Administration ("NMPA") (formerly, the China FDA) has accepted the investigational new drug (IND) application for rimegepant, Biohaven's lead oral calcitonin gene-related peptide (CGRP) receptor antagonist product candidate, for the treatment of migraine

  6. Berkeley Lights Launches Plasma B Cell Antibody Discovery Workflow On The Beacon® Optofluidic Platform
    1/5/2019

    Berkeley Lights, Inc. (BLI), a leader in digital cell biology, announced today the release of a plasma B cell antibody discovery workflow for use on the Beacon Optofluidic Platform

  7. Horizon Pharma plc And HemoShear Therapeutics Enter Into Exclusive Drug Discovery Collaboration In Gout
    1/3/2019

    Horizon Pharma plc and HemoShear Therapeutics, LLC, a privately held biotechnology company, recently announced a collaboration to discover and develop novel therapeutics for gout

  8. Ablexis Announces Licensing Agreement With Corvidia Therapeutics
    1/3/2019

    Ablexis, LLC, a biopharmaceutical company focused on licensing its AlivaMab Mouse technology for antibody drug discovery, recently announced a license agreement with Corvidia Therapeutics Inc

  9. A New 'Atlas' Of Genetic Influences On Osteoporosis
    1/3/2019

    A ground-breaking new study led by researchers from the Lady Davis Institute (LDI) at the Jewish General Hospital (JGH) has succeeded in compiling an atlas of genetic factors associated with estimated bone mineral density (BMD), one of the most clinically relevant factors in diagnosing osteoporosis

  10. Novartis Provides Data To SPARK, Pew's Platform For Antibiotic Discovery Research
    1/3/2019

    The Pew Charitable Trusts announced today that Novartis has shared data from its antibiotic research programs on Pew's open-access Shared Platform for Antibiotic Research and Knowledge (SPARK)